Page last updated: 2024-11-06

5-(3-hydroxyphenyl)-5-phenylhydantoin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-(3-hydroxyphenyl)-5-phenylhydantoin: metabolite of phenytoin; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91597
CHEMBL ID1908020
SCHEMBL ID2895847
MeSH IDM0089009

Synonyms (23)

Synonym
m-hydroxydiphenylhydantoin
3-hydroxy phenytoin
5-(3-hydroxyphenyl)-5-phenyl hydantoin
FT-0669966
5-(3-hydroxyphenyl)-5-phenylimidazolidine-2,4-dione
4-(m-hydroxyphenyl)-4-phenylperhydroimidazole-2,5-dione
einecs 250-025-8
5-(m-hydroxyphenyl)-5-phenylhydantoin
5-(3-hydroxyphenyl)-5-phenylhydantoin
30074-03-4
CHEMBL1908020
SCHEMBL2895847
5-(3-hydroxyphenyl)-5-phenyl-2,4-imidazolidinedione #
2,4-imidazolidinedione, 5-(3-hydroxyphenyl)-5-phenyl-
FSPRLRPJSPWQNC-UHFFFAOYSA-N
AKOS030239867
J-017761
5-m-hydroxyphenyl-5-phenylhydantoin
DTXSID30952482
4-(3-hydroxyphenyl)-4-phenyl-4h-imidazole-2,5-diol
HY-145671
CS-0378669
5-(3-hydroxyphenyl)-5-phenyl-2,4- imidazolidinedione;

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"0004); and the apparent elimination half-life increased from 16."( Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers.
Bliss, M; Gear, K; Hoyer, GL; Marcus, FI; Nolan, PE, 1989
)
0.28

Bioavailability

ExcerptReferenceRelevance
"8 mg/kg of body weight, IV and PO) to 6 horses to determine bioavailability (F)."( Disposition, elimination, and bioavailability of phenytoin and its major metabolite in horses.
Birks, EK; Guan, F; Rudy, JA; Soma, LR; Teleis, DC; Tsang, DS; Uboh, CE; Watson, AO, 2001
)
0.31

Dosage Studied

ExcerptRelevanceReference
" The DPH/HPPH ratios in plasma specimens showed excellent correlation with the plasma half-lives of DPH and average steady-state levels, suggesting that this ratio could provide guidance in the selection of optimum dosage regimens for problem patients."( Phenytoin metabolism in subjects with long and short plasma half-lives.
Buchanan, RA; Chang, T; Dill, WA; Glazko, AJ; Peterson, FE; Smith, TC, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (53.85)18.7374
1990's9 (34.62)18.2507
2000's3 (11.54)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.71 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.11 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.57%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]